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Africa, especially sub-Saharan Africa, carries a 
significant burden of communicable and non-
communicable diseases. The relative distribution of 
these is projected to shift by 2030.[1] By 2012, 25 million 
people in the sub-region were living with HIV/AIDS, 
comprising 70.8% of the global disease burden.[2] Regionally, cancer is 
an emerging public health problem.[3] In 2008 there were 715 000 new 
cases and 542 000 cancer-related deaths in Africa. This is projected to 
nearly double by 2030 due to population growth and ageing,[4] with 
36% of cancers infection-related, twice the global average.[5]
With this significant disease burden, compounded by other 
life-limiting illnesses, a clear public health argument exists for the 
availability of pain- and symptom-relieving medicines to enhance 
the quality of life of millions of affected people, maximise the clinical 
benefit of available treatments, and ensure freedom from unnecessary 
suffering.[6] Indeed, effective pain alleviation is a central pillar of 
the World Health Organization (WHO’s) enhanced public health 
approach for developing palliative care services[7] and well established 
in its three-step analgesic ladder.[8]
In mid-September 2013, the first session of the African Ministers 
of Health on palliative care was held at the joint conference of 
the African Palliative Care Association/Hospice Palliative Care 
Association of South Africa, in Johannesburg, South Africa (SA). 
Delegates underscored this argument by adopting a consensus 
statement proposing, as part of six objectives:
‘The use of the already established global and regional frameworks 
provided by the African Union and World Health Organization, 
to ensure availability of, and access to, essential medicines and 
technologies for the treatment of pain and other symptoms being 
experienced by so many in Africa, including children. This includes 
the procurement and distribution of morphine, to ensure greater 
availability and access of this main opioid for the management of 
moderate to severe pain.’[9]
However, despite advances in provision on the continent,[10] 
millions of people cannot access palliative care in general and 
effective pain medicines specifically, despite the significant 
prevalence of pain among those with life-limiting diagnoses. For 
example, Namisango et al.[11] found that among 302 ambulatory 
HIV/AIDS patients in Uganda, 47% reported pain in the seven 
days prior to the survey, while pain was a symptom at the time 
of diagnosis for 68%, and 27% reported severe pain on a 0-to-10 
numeric scale, with a resultant debilitating effect on quality of life. 
These prevalence figures were echoed by Harding et al.,[12]  who 
reported a seven-day period prevalence of pain at 82.6% among 
224 HIV-infected patients in five palliative care centres in SA and 
Uganda. Similarly, Mphahlele et al.[13]  compared predominantly 
black African and female HIV-positive patients attending rural 
and metropolitan outpatient clinics in SA and found that 72% of 
rural and 56% of metropolitan participants reported having pain at 
the time of interview which was comparably moderate to severe in 
intensity among both populations. 
Because of the very high prevalence of cancer patients presenting 
with advanced and incurable disease, to clinical services with 
limited infrastructure, many affected Africans endure a painful and 
distressing death. Indeed, Harding et al.’s[14] investigation of symptom 
prevalence and burden among advanced cancer patients in two 
African countries found that among 112 patients, pain was the most 
prevalent of a mean of 18 symptoms (87.5%), and ranked as most 
severe (23.2%).
In spite of this overwhelming need, in many African countries access 
to even the simplest pain-relieving medication is restricted. While 
many countries have shown an increase in opioid consumption 
since 2000, all African countries, apart from SA, have very low 
consumption levels, as defined by the International Narcotics Control 
Board, with a defined daily dose of less than 200 mg/day/100 000 
people.[15] Many barriers hamper the availability and accessibility 
of effective pain medications. Harding et al.’s[16] study of drug 
availability and prescribing practices in 12 sub-Saharan African 
countries found that, in addition to problems accessing non-opioids, 
less than half of the responding 62 service facilities were prescribing 
opioids of any strength.
The striking gulf between clinical need and available supply 
of effective medicines in Africa was recently highlighted by an 
international study reporting that, globally, governments are leaving 
hundreds of millions of cancer patients to suffer needlessly because of 
their failure to ensure adequate access to pain-relieving medicines. [17] 
Published in the Annals of Oncology, the paper by Cleary et al.[17] is 
the product of the International Collaborative Project to Evaluate 
the Availability and Accessibility of Opioids for the Management 
of Cancer Pain.[18] Initiated by the European Society for Medical 
Oncology, the study was co-ordinated with the European Association 
for Palliative Care, the Pain and Policies Study Group at the US-based 
University of Wisconsin Carbone Cancer Center, the Union for 
International Cancer Control and the WHO, and assisted by the 
co-operation and participation of a further 17 international oncology 
and palliative care organisations, including the Uganda-based African 
Palliative Care Association.
With data gathered between December 2010 and July 2012, 156 
reports were submitted to the study team by experts in 76 countries 
and 25 Indian states, representing 58% of countries and 83% of 
5.7 billion of the people living in Africa, Asia, the Middle East, 
Latin and Central America and the Caribbean. The African report 
incorporates data from 25 of the 52 countries surveyed, and covers 
744 million of the region’s 1 127 million people (66%).
The researchers found that codeine and morphine were the 
primary medicines on formulary, with no one country having all 
seven of the formulations considered essential for the relief of cancer 
pain: codeine, immediate- and slow-release oral morphine, injectable 
morphine, oral oxycodone, oral methadone and transdermal 
fentanyl. [19] Six countries (Côte d’Ivoire, Liberia, Libya, Rwanda, 
Sierra Leone and Tunisia) reported that they had no immediate-
release morphine, four had no sustained-release morphine (Libya, 
Sierra Leone, Tanzania and Zimbabwe), and two had no injectable 
morphine (Ethiopia and Malawi). Only 15 countries had all oral 
immediate-release, oral sustained-release and injectable morphine 
available. Sierra Leone and Tanzania had the most limited formulary, 
with only two medications on formulary.
In approximately half the countries, most of the medicines were 
free. Otherwise the full cost of medications was borne by patients. 
Regulatory barriers, with evidence of over-regulation that impedes 
patient care, were widespread. Most countries used a wide number 
of regulatory restriction types to limit the accessibility of opioids, 
ranging from two in Botswana and Namibia, to seven in Egypt 
and Mauritius. More specifically, the majority of countries (16/25) 
required special authorisation for outpatients with cancer pain to 
receive an opioid prescription, and similar restrictions were reported 
in 14 countries for inpatients and in 11 countries even for hospice 
patients. Only six countries (Côte d’Ivoire, Malawi, Mauritius, 
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Nigeria, Tanzania and Zimbabwe) allowed cancer patients to receive 
opioid medications without requiring registration or a special permit.
Lastly, while few countries had restrictions limiting physician 
prescribing, three (Egypt, Liberia and Morocco) required a special 
permit for family doctors and surgeons and even for oncologists. 
Prescription limitations were commonplace and ten countries did not 
allow physicians to prescribe more than two weeks’ supply of opioid 
analgesics to a patient.
The survey demonstrates that in many countries across Africa, 
government regulations are undermining the ability to provide pain 
relief to cancer patients, as well as those with other life-limiting 
illnesses. 
Many other issues affect the availability and use of appropriate 
pain-relieving medicines on the continent. These include problems 
of supply and distribution, a misplaced ‘opiophobia’ among both 
patients and providers, a related limited understanding of how and 
when to use opioids, and the restriction of prescribing powers to 
doctors, rather than extending them (as in Uganda) to appropriately 
trained nurses working in rural areas.
Nevertheless, there is a growing recognition among national 
governments of the importance of palliative care and access to 
effective pain relief, as illustrated by the African Union’s issuance 
of a common position statement on controlled substances and 
access to pain management medicines in October 2012,[20] and the 
consensus statement of the health ministers meeting in 2013. [9] 
However, this can only be translated into action if and when 
known obstacles – such as the restrictive regulatory barriers 
described in the survey[17] – are addressed as part of the systems-
strengthening agenda. If not, the untreated epidemic of pain will 
continue.
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